Financials Oculis Holding AG

Equities

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq 06:00:00 2024-05-27 pm EDT 5-day change 1st Jan Change
11.9 USD +0.42% Intraday chart for Oculis Holding AG +0.42% +5.97%

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 153.1 345.7 443.5 - -
Enterprise Value (EV) 1 153.1 254 363.5 418.4 450.2
P/E ratio -0.72 x -3.18 x -6.29 x -5.84 x -5.67 x
Yield - - - - -
Capitalization / Revenue - 391 x 475 x 45.8 x 13.2 x
EV / Revenue - 288 x 389 x 43.2 x 13.4 x
EV / EBITDA - -3.16 x -6.6 x -11.1 x 59.3 x
EV / FCF - -4.68 x -7.56 x -8.57 x -4.91 x
FCF Yield - -21.4% -13.2% -11.7% -20.4%
Price to Book - 3.69 x 3.46 x 4.84 x 4.52 x
Nbr of stocks (in thousands) 16,399 36,598 41,740 - -
Reference price 2 9.336 9.445 10.63 10.63 10.63
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 0.883 0.934 9.686 33.71
EBITDA 1 - -80.43 -55.06 -37.74 7.594
EBIT 1 - -80.71 -64.97 -66.5 -47.99
Operating Margin - -9,140.88% -6,956.9% -686.58% -142.39%
Earnings before Tax (EBT) 1 - -88.7 -65.69 -72.31 -70.38
Net income 1 -38.7 -88.8 -65.46 -74.54 -81.17
Net margin - -10,056.85% -7,008.92% -769.61% -240.84%
EPS 2 -12.94 -2.970 -1.690 -1.821 -1.876
Free Cash Flow 1 - -54.26 -48.1 -48.8 -91.7
FCF margin - -6,144.85% -5,150.11% -503.83% -272.06%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - - - - -
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.25 - 0.219 0.185 0.222 0.2603 0.2541 0.2215 - -
EBITDA - - -12.89 -12.11 - - - - - -
EBIT 1 -10.74 - -12.96 -12.18 -15.33 -15.78 -16.36 -17.54 - -
Operating Margin -4,298% - -5,917.35% -6,585.95% -6,904.5% -6,060.03% -6,436.35% -7,916.71% - -
Earnings before Tax (EBT) 1 -12.76 - -17.53 -12.51 -16.06 -15.88 -16.48 -17.13 - -
Net income 1 -12.88 - -17.41 -12.5 -16.09 -15.77 -16.33 -17.37 - -
Net margin -5,150.8% - -7,951.14% -6,756.22% -7,249.1% -6,056.02% -6,425.76% -7,838.44% - -
EPS 2 -0.3800 -2.530 -0.4800 -0.3400 -0.4400 -0.4125 -0.4208 -0.4408 -0.3700 -0.3700
Dividend per Share - - - - - - - - - -
Announcement Date 8/29/23 8/29/23 11/15/23 3/18/24 5/8/24 - - - - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - 6.69
Net Cash position 1 - 91.7 80 25.1 -
Leverage (Debt/EBITDA) - - - - 0.8805 x
Free Cash Flow 1 - -54.3 -48.1 -48.8 -91.7
ROE (net income / shareholders' equity) - - -80.6% - 6.86%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - 2.560 3.070 2.190 2.350
Cash Flow per Share 2 - -1.800 -1.990 -2.470 -
Capex 1 - 0.05 0.4 0.4 0.4
Capex / Sales - 5.44% 42.83% 4.13% 1.19%
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.63 CHF
Average target price
25.75 CHF
Spread / Average Target
+142.37%
Consensus
  1. Stock Market
  2. Equities
  3. OCS Stock
  4. Financials Oculis Holding AG